Deutsche Bank’s Top Q3 Healthcare Stocks: PFE, MRK, JNJ, GILD

Wall St. Watchdog reveals information regarding Deutsche Bank’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 526 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $7.142 billion.

  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, Deutsche Bank reported holding 42,173,920 shares with a market value of $868,782,768. This comprised 0.78% of the total portfolio. On 09/30/2011, Deutsche Bank reported holding 35,042,707 shares with a market value of $619,555,070. This comprised 0.77% of the total portfolio. The net change in shares for this position over the two quarters is -7,131,213. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, Deutsche Bank reported holding 16,569,716 shares with a market value of $584,745,293. This comprised 0.53% of the total portfolio. On 09/30/2011, Deutsche Bank reported holding 14,715,226 shares with a market value of $481,187,901. This comprised 0.6% of the total portfolio. The net change in shares for this position over the two quarters is -1,854,490. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, Deutsche Bank reported holding 8,644,895 shares with a market value of $575,058,386. This comprised 0.52% of the total portfolio. On 09/30/2011, Deutsche Bank reported holding 6,631,517 shares with a market value of $422,361,309. This comprised 0.52% of the total portfolio. The net change in shares for this position over the two quarters is -2,013,378. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Gilead Sciences Inc. (NASDAQ:GILD): On 06/30/2011, Deutsche Bank reported holding 11,980,699 shares with a market value of $496,120,744. This comprised 0.45% of the total portfolio. On 09/30/2011, Deutsche Bank reported holding 9,254,842 shares with a market value of $359,087,863. This comprised 0.44% of the total portfolio. The net change in shares for this position over the two quarters is -2,725,857. About Company: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
  • Eli Lilly & Co. (NYSE:LLY): On 06/30/2011, Deutsche Bank reported holding 9,277,187 shares with a market value of $348,172,817. This comprised 0.31% of the total portfolio. On 09/30/2011, Deutsche Bank reported holding 7,534,586 shares with a market value of $278,553,654. This comprised 0.34% of the total portfolio. The net change in shares for this position over the two quarters is -1,742,601. About Company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011, Deutsche Bank reported holding 9,584,719 shares with a market value of $277,573,453. This comprised 0.25% of the total portfolio. On 09/30/2011, Deutsche Bank reported holding 8,166,774 shares with a market value of $256,273,361. This comprised 0.32% of the total portfolio. The net change in shares for this position over the two quarters is -1,417,945. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Medtronic Inc. (NYSE:MDT): On 06/30/2011, Deutsche Bank reported holding 8,070,401 shares with a market value of $310,952,541. This comprised 0.28% of the total portfolio. On 09/30/2011, Deutsche Bank reported holding 7,636,891 shares with a market value of $253,850,270. This comprised 0.31% of the total portfolio. The net change in shares for this position over the two quarters is -433,510. About Company: Medtronic, Inc. develops therapeutic and diagnostic medical products. The Company’s principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. Medtronic’s products are sold worldwide.
  • Celgene Corporation (NASDAQ:CELG): On 06/30/2011, Deutsche Bank reported holding 4,083,166 shares with a market value of $246,296,572. This comprised 0.22% of the total portfolio. On 09/30/2011, Deutsche Bank reported holding 3,789,649 shares with a market value of $234,617,169. This comprised 0.29% of the total portfolio. The net change in shares for this position over the two quarters is -293,517. About Company: Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
  • Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): On 06/30/2011, Deutsche Bank reported holding 5,360,775 shares with a market value of $258,496,577. This comprised 0.23% of the total portfolio. On 09/30/2011, Deutsche Bank reported holding 5,584,119 shares with a market value of $207,840,916. This comprised 0.26% of the total portfolio. The net change in shares for this position over the two quarters is 223,344. About Company: Teva Pharmaceutical Industries Ltd. develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. The Company produces antibiotics, oncological products, Alpha D3 for treatment of post-menopausal bone loss in women and Copaxone for treatment of multiple sclerosis. Teva develops novel drugs for diseases of the central nervous system.
  • Abbott Laboratories (NYSE:ABT): On 06/30/2011, Deutsche Bank reported holding 5,032,968 shares with a market value of $264,834,771. This comprised 0.24% of the total portfolio. On 09/30/2011, Deutsche Bank reported holding 3,408,166 shares with a market value of $174,293,607. This comprised 0.22% of the total portfolio. The net change in shares for this position over the two quarters is -1,624,802. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.

(Note: Data regarding Deutsche Bank’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet